2,4-Dimethoxy-6-methylbenzene-1,3-diol

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,4-Dimethoxy-6-methylbenzene-1,3-diol
• 英文别名: 2,4-dimethoxy-6-methylbenzene-1,3-diol
• 化学式: C₉H₁₂O₄
• 分子量: 184.19
• InChiKey: STXRLTSAXAWSTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof
  申请人：National Taiwan University

  公开号：EP2329816A1

  公开（公告）日：2011-06-08

  An anti-cancer active substance from Antrodia Cinnamomea, produced from mycelium of Antrodia Cinnamomea with following steps: (1) culturing mycelium of Antrodia Cinnamomea by liquid fermentation ; (2) extracting the thus-obtained mycelium with ethanol and concentrating the extracted solution to obtain an ethanol extract ; (3) dissolving said ethanol extract in water, and extracting with equal volume of ethyl acetate to obtain ethyl acetate extrct ; (4) purifying said ethyl acetate extract by silica gel column chromatography using hexane/ethyl acetate gradient as the mobile phase to obtain an eluate fraction g ; and (5) purifying said eluate fraction g by silica gel column chromatography using hexane/ethyl acetate gradient as the mobile phase to obtain a specific eluate fraction which could be purified further to obtain said anti-cancer active substance from Antrodia Cinnamomea.

  一种肉桂蝙蝠蛾抗癌活性物质，由肉桂蝙蝠蛾菌丝体经以下步骤制得：(1) 用液体发酵法培养肉桂蝙蝠蛾菌丝体；(2) 用乙醇提取由此获得的菌丝体，浓缩提取液，得到乙醇提取物；(3) 将所述乙醇提取物溶于水，用等体积的乙酸乙酯提取，得到乙酸乙酯提取物；(4) 以正己烷/乙酸乙酯梯度为流动相，采用硅胶柱层析法纯化所述乙酸乙酯提取物，得到洗脱液馏分 g；以及 (5) 以正己烷/乙酸乙酯梯度为流动相，采用硅胶柱层析法纯化所述洗脱液馏分 g，得到特异性洗脱液馏分，进一步纯化得到所述肉桂蕨抗癌活性物质。
• Use and pharmaceutical composition for liver fibrosis prevention and/or treatment
  申请人：Cojet Biotech Inc.

  公开号：US10945991B2

  公开（公告）日：2021-03-16

  The present disclosure discloses an extract of Antrodia cinnamomea and pharmaceutical application thereof. As confirmed by the researches of the present disclosure, said extract of Antrodia cinnamomea is able to decrease the activities of hepatic stellate cell and therefore obtain the efficacy of liver fibrosis prevention and/or treatment. Accordingly, the present disclosure discloses a novel pharmaceutical application of Antrodia cinnamomea and provides an alternative prevention and/or treatment regime of liver fibrosis for the field.

  本公开披露了一种肉桂蕨提取物及其药物应用。 经本公开的研究证实，所述肉桂酚提取物能够降低肝星状细胞的活性，从而获得预防和/或治疗肝纤维化的功效。 因此，本公开披露了一种新型的肉桂蚂蚁药学应用，并为该领域提供了一种可供选择的肝纤维化预防和/或治疗方案。
• ANTI-CANCER ACTIVE SUBSTANCE FROM ANTRODIA CAMPHORATA, METHOD FOR PREPARING THE SAME AND USE THEREOF
  申请人：CHIANG Been-Huang

  公开号：US20110123562A1

  公开（公告）日：2011-05-26

  An anti-cancer active substance from Antrodia Camphorata , produced from mycelium of Antrodia Camphorata by following steps: ( 1 ) culturing mycelium of Antrodia Camphorata by liquid fermentation; ( 2 ) extracting the thus-obtained mycelium with ethanol and concentrating the extracted solution to obtain an ethanol extract; ( 3 ) dissolving the ethanol extract in water, and extracting with equal volume of ethyl acetate to obtain ethyl acetate extract; ( 4 ) purifying the ethyl acetate extract by silica gel column chromatography using hexane/ethyl acetate gradient as the mobile phase to obtain an eluate fraction g; and ( 5 ) purifying the eluate fraction g by silica gel column chromatography using hexane/ethyl acetate gradient as the mobile phase to obtain a specific eluate fraction which could be purified further to obtain the anti-cancer active substance from Antrodia Camphorata.
• METHODS FOR ASSISTING ANTI-CANCER DRUGS
  申请人：Yeh Wen-Li

  公开号：US20130089534A1

  公开（公告）日：2013-04-11

  A method for assisting an anti-cancer drug comprising administrating an effective amount of Antrodia camphorata fermentation solution to improve life quality of patient suffering from cancers after chemotherapy is provided.
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170042912A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.